Poly(Adenosine Diphosphate–Ribose) Polymerase Inhibitors in Cancer Treatment

Volume: 26, Issue: 3, Pages: 649 - 670
Published: Jun 1, 2012
Abstract
Recently, the development of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors as a synthetic lethality approach has brought a major breakthrough in the treatment of breast cancer susceptibility gene (BRCA)-mutant cancers. Because sporadic cancers have also been found to commonly have other defects in DNA repair, PARP inhibitors are under active clinical investigation in combination with DNA-damaging therapeutics in a wide range of...
Paper Details
Title
Poly(Adenosine Diphosphate–Ribose) Polymerase Inhibitors in Cancer Treatment
Published Date
Jun 1, 2012
Volume
26
Issue
3
Pages
649 - 670
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.